GlassScriptPhysician profile
Ryan Parker Mcdonald
NPI 1194915561
$3,285.41
in general payments reported to CMS, 2019-2025
32 companies · $931 in 2025
The $931 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $164 · 2021: $254 · 2022: $217 · 2023: $804 · 2024: $733 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $532.83 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $518.28 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $329.75 | 2021-2025 | |
| Amgen INC. | $311.77 | 2020-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $201.37 | 2019-2025 | Lokelma, Evusheld, Farxiga |
| Vifor Pharma, INC. | $166.74 | 2020-2025 | Veltassa |
| Ardelyx, INC. | $161.74 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Horizon Therapeutics Plc | $139.02 | 2021-2023 | Krystexxa |
| Boston Scientific Corporation | $130.72 | 2019-2024 | |
| Travere Therapeutics, INC. | $124.00 | 2019-2025 | |
| Bard Peripheral Vascular, INC. | $115.64 | 2023 | |
| Calliditas Therapeutics US INC. | $84.01 | 2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $59.60 | 2022-2023 | Benlysta |
| Xeris Pharmaceuticals, INC. | $44.35 | 2021-2024 | Keveyis |
| Ani Pharmaceuticals, INC. | $41.43 | 2024-2025 | Purified Cortrophin Gel |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cala Health, INC. | $41.16 | 2025 | Cala Kiq |
| Mallinckrodt Hospital Products INC. | $31.20 | 2025 | Terlivaz |
| Lilly USA, LLC | $31.12 | 2024 | Jardiance |
| Novo Nordisk INC | $27.97 | 2024 | Wegovy, Rybelsus, Ozempic |
| Baxter Healthcare | $27.51 | 2024 | Hillrom - Life 2000 Ventilation System |
| Akebia Therapeutics INC | $18.58 | 2025 | Vafseo |
| Medtronic, INC. | $18.42 | 2025 | Minimed 780g |
| Cycle Pharmaceuticals INC | $17.95 | 2025 | Venxxiva |
| Treace Medical Concepts, INC. | $15.57 | 2024 | |
| Fresenius USA Marketing, INC. | $14.82 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.35 | 2021 | |
| Cormedix INC. | $14.06 | 2024 | Defencath |
| Nxstage Medical, INC. | $13.35 | 2019 | |
| Azurity Pharmaceuticals, INC. | $13.22 | 2023 | Horizant |
| Janssen Pharmaceuticals, INC | $12.86 | 2023 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.02 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.